Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) dropped 4.9% during trading on Monday . The stock traded as low as $5.03 and last traded at $5.16. Approximately 377,782 shares changed hands during trading, a decline of 87% from the average daily volume of 2,873,468 shares. The stock had previously closed at $5.42.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. Truist Financial initiated coverage on Solid Biosciences in a research report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price on the stock. Wedbush assumed coverage on Solid Biosciences in a research note on Friday, December 13th. They issued an "outperform" rating and a $16.00 price target on the stock. JMP Securities started coverage on Solid Biosciences in a research note on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price objective on the stock. Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research note on Thursday. Nine investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $15.70.
View Our Latest Report on SLDB
Solid Biosciences Stock Up 0.1 %
The business has a 50-day moving average price of $4.18 and a 200-day moving average price of $5.47. The company has a market capitalization of $399.48 million, a price-to-earnings ratio of -1.68 and a beta of 1.98.
Institutional Trading of Solid Biosciences
Several large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Solid Biosciences in the third quarter worth approximately $293,000. Valence8 US LP bought a new stake in Solid Biosciences during the third quarter worth approximately $110,000. The Manufacturers Life Insurance Company acquired a new position in Solid Biosciences in the 3rd quarter valued at $71,000. FMR LLC bought a new position in shares of Solid Biosciences in the third quarter worth about $305,000. Finally, MetLife Investment Management LLC lifted its holdings in shares of Solid Biosciences by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,699 shares of the company's stock worth $95,000 after buying an additional 7,719 shares during the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.
Solid Biosciences Company Profile
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
See Also
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
